The HIV drug class called "non-nucleoside reverse transcriptase inhibitors," or NNRTIs, must have something of an inferiority complex.
California's expansion of Medicaid under the Affordable Care Act enabled many low-income HIV patients to get health insurance previously denied to them. Still, those with mental health needs, who had been receiving coordinated care through a separate federal program, suddenly faced gaps in treatment, payment disputes and doctors who had little understanding of life with HIV.
There are multiple reasons why re-entry into communities from prison for black men with HIV is a difficult proposition, according to a recent study published in Social Science and Medicine. The researchers show that the intersectionality framework is applicable to understanding the challenges these men face after serving time in prison.
Earlier this year, I wrote a piece about friends and colleagues of mine who have left HIV clinical practice. Something about it touched a nerve. It's one of the most commented-on pieces in the history of this blog.
The International AIDS Conference -- or "AIDS 2018" -- returned to Amsterdam for the first time since 1992.
The latest HIV drug approval from the FDA came this past week with the release of a single-tablet treatment containing the following drugs:
After the United States' recent opposition to a World Health Organization (WHO) resolution promoting breastfeeding, U.S. president Donald Trump said that infant formula was needed especially for women in resource-poor situations. However, that's exactly when breastfeeding is safer than formula, Michele Barry, M.D., FACP, of the Stanford School of Medicine, argued in a New York Times article on this controversy.
Highly regarded for his contributions to cancer research in people with HIV, Dr. Sigel is Assistant Professor of Medicine in the Division of General Internal Medicine and the Division of Infectious Diseases at the Icahn School of Medicine at Mount Sinai in New York City. With a focus on two non-AIDS-defining malignancies -- lung cancer and anal cancer -- Dr. Sigel has led numerous innovative studies on these conditions and others in people with HIV. His work addresses unique aspects of HIV-related malignancy, including risk, prevention, treatment, and prognosis. He cochairs the Cancer Core of the Veterans Aging Cohort Study, a large longitudinal comparison of HIV-positive and -negative veterans with equivalent access to care and a high lung cancer burden. With an MD and a Masters in Public Health from the University of North Carolina and a PhD from Mount Sinai, Dr. Sigel devotes time to the primary care of people with HIV infection and hepatitis C infection. His many speaking invitations include talks at Yale University, the University of Massachusetts, and the University of North Carolina.
By the looks of my Instagram feed and this month's events calendar, everything is going great for LGBTQ people. The bright colors and loud music are a good balm to ward off the extra stress we carry with us as sexual and gender minorities; lesbians; gay men; and bisexual, transgender, non-binary, and intersex people. What bad day couldn't be helped by a little glitter?
Last week, in response to newly available surveillance data, multiple agencies issued a warning about the HIV integrase inhibitor dolutegravir (DTG) and pregnancy. The warnings cite an increased risk of neural tube defects in babies born to women who became pregnant while receiving the drug.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.